Concerning the relationship between IL-17 serum levels and the MM patient’s survival and therapeutic response, the possible mechanisms are that elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function by IL-17A receptor (IL-17RA) expressed on tumor cells (21, 38). This evidence concerns the gene IL17RA and plasma cell myeloma.